Ra Capital Management Has Lifted Its Tg Therapeutics (TGTX) Stake by $23.48 Million as Stock Price Declined; Home Depot (HD) Shareholder Alethea Capital Management Has Lifted Its Stake

The Home Depot, Inc. (NYSE:HD) Logo

Ra Capital Management Llc increased its stake in Tg Therapeutics Inc (TGTX) by 73.07% based on its latest 2018Q2 regulatory filing with the SEC. Ra Capital Management Llc bought 1.81 million shares as the company’s stock declined 18.33% while stock markets rallied. The hedge fund held 4.28M shares of the health care company at the end of 2018Q2, valued at $56.27M, up from 2.47 million at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Tg Therapeutics Inc for a number of months, seems to be bullish on the $384.14 million market cap company. The stock decreased 0.79% or $0.04 during the last trading session, reaching $5. About 953,174 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has declined 4.55% since December 8, 2017 and is downtrending. It has underperformed by 20.17% the S&P500. Some Historical TGTX News: 24/04/2018 – TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multip; 06/03/2018 TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update; 17/05/2018 – TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Onco; 23/04/2018 – DJ TG Therapeutics Inc, Inst Holders, 1Q 2018 (TGTX); 07/04/2018 – TG Therapeutics Access Event Scheduled By B. Riley FBR, Inc; 19/04/2018 – TG Therapeutics Closes Above 50-Day Moving Average: Technicals; 08/05/2018 – TGTX TO REPORT FILING DECISION ON FIRST BLA/NDA LATER IN YEAR; 15/03/2018 – TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annua; 24/04/2018 – TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting; 24/04/2018 – TG Therapeutics Announces Updated Results From the Ongoing Phase 2 Study of Ublituximab (TG-1101)

Alethea Capital Management Llc increased its stake in Home Depot Inc (HD) by 178.9% based on its latest 2018Q2 regulatory filing with the SEC. Alethea Capital Management Llc bought 3,578 shares as the company’s stock rose 5.83% with the market. The institutional investor held 5,578 shares of the consumer services company at the end of 2018Q2, valued at $1.09 million, up from 2,000 at the end of the previous reported quarter. Alethea Capital Management Llc who had been investing in Home Depot Inc for a number of months, seems to be bullish on the $195.17 billion market cap company. The stock decreased 1.80% or $3.17 during the last trading session, reaching $172.79. About 6.23 million shares traded or 9.91% up from the average. The Home Depot, Inc. (NYSE:HD) has risen 32.56% since December 8, 2017 and is uptrending. It has outperformed by 16.94% the S&P500. Some Historical HD News: 24/04/2018 – FOX 12 Oregon KPTV: #BREAKING: Two Dallas police officers shot, critically wounded at Home Depot; 14/05/2018 – Home Depot well placed to withstand ”Amazon effect,” investors say; 21/03/2018 – New York Post: Austin bomber purchased materials at Home Depot; 15/05/2018 – HOME DEPOT CFO SAYS MONTH TO DATE, MAY COMP SALES ARE DOUBLE DIGIT POSITIVE- CONF CALL; 24/04/2018 – BNO News: BREAKING: At least 3 people, including 2 police officers, have been shot near Home Depot in northeast Dallas – WFAA; 16/05/2018 – Home Depot Presenting at AllianceBernstein Conference May 31; 17/05/2018 – HOME DEPOT INC HD.N SETS QUARTERLY DIVIDEND OF $1.03/SHR; 14/05/2018 – Home Depot employees share 10 insider facts many shoppers don’t know; 25/04/2018 – ABC7 Eyewitness News: #BREAKING: Dallas mayor says 1 officer has died day after shooting at Home Depot; 15/03/2018 – CPSC: CAMERON CO. RECALLS CHILDREN’S TENTS SOLD AT HOME DEPOT

More notable recent The Home Depot, Inc. (NYSE:HD) news were published by: Benzinga.com which released: “Home Depot, Inc. (The) (NYSE:HD) – 2 Charts That Show Why Home Depot Will Continue Falling This Week – Benzinga” on November 19, 2018, also Seekingalpha.com with their article: “Lowe’s bounces 3% despite Stifel downgrade – Seeking Alpha” published on November 21, 2018, Seekingalpha.com published: “Home Depot -2% after BAML cut – Seeking Alpha” on November 16, 2018. More interesting news about The Home Depot, Inc. (NYSE:HD) were released by: Seekingalpha.com and their article: “Home Depot: A Retail Winner – Seeking Alpha” published on November 12, 2018 as well as Seekingalpha.com‘s news article titled: “When Is Home Depot A Buy? – Seeking Alpha” with publication date: November 19, 2018.

Since August 16, 2018, it had 4 insider purchases, and 5 selling transactions for $27.72 million activity. Hewett Wayne M. bought $42,405 worth of stock or 250 shares. On Thursday, August 16 the insider Campbell Ann Marie sold $3.81 million. VADON MARK C had bought 11,500 shares worth $2.00 million on Monday, November 19. $354,960 worth of The Home Depot, Inc. (NYSE:HD) shares were bought by Kadre Manuel. Shares for $21.17 million were sold by Menear Craig A. $2.19M worth of stock was sold by Lennie William G. on Monday, August 20.

Among 36 analysts covering The Home Depot Inc. (NYSE:HD), 23 have Buy rating, 0 Sell and 13 Hold. Therefore 64% are positive. The Home Depot Inc. had 130 analyst reports since August 19, 2015 according to SRatingsIntel. The company was initiated on Tuesday, October 3 by Gordon Haskett Capital Corporation. Robert W. Baird maintained the stock with “Buy” rating in Friday, October 13 report. Guggenheim maintained The Home Depot, Inc. (NYSE:HD) on Tuesday, January 30 with “Buy” rating. The rating was maintained by Telsey Advisory Group on Monday, December 4 with “Outperform”. Morgan Stanley maintained it with “Buy” rating and $210.0 target in Wednesday, March 21 report. Citigroup maintained it with “Buy” rating and $155 target in Wednesday, August 17 report. Jefferies maintained it with “Buy” rating and $182.0 target in Wednesday, September 13 report. The stock of The Home Depot, Inc. (NYSE:HD) earned “Buy” rating by UBS on Friday, January 26. Robert W. Baird maintained the shares of HD in report on Tuesday, January 2 with “Buy” rating. The firm has “Buy” rating given on Thursday, July 20 by Stifel Nicolaus.

Investors sentiment increased to 1.14 in 2018 Q2. Its up 0.27, from 0.87 in 2018Q1. It improved, as 44 investors sold HD shares while 584 reduced holdings. 142 funds opened positions while 572 raised stakes. 764.62 million shares or 0.98% less from 772.16 million shares in 2018Q1 were reported. Verus Financial Prns holds 1,044 shares or 0.08% of its portfolio. Lenox Wealth Mgmt Inc holds 0.23% of its portfolio in The Home Depot, Inc. (NYSE:HD) for 3,734 shares. Oppenheimer Asset, a New York-based fund reported 72,804 shares. Concorde Asset Lc holds 1,259 shares or 0.28% of its portfolio. Prentiss Smith reported 100 shares or 0.01% of all its holdings. Advent Mngmt De accumulated 2,000 shares or 0.01% of the stock. 2,029 were accumulated by Hall Laurie J Trustee. Barometer Cap invested in 97,155 shares. Gofen & Glossberg Lc Il holds 0.58% or 79,542 shares. Lincoln Cap Ltd reported 3,058 shares or 0.32% of all its holdings. Cypress Asset Mngmt Tx stated it has 32,568 shares. Verition Fund Ltd Liability Corp owns 1,707 shares for 0.02% of their portfolio. Oppenheimer And Co holds 138,227 shares. Willingdon Wealth stated it has 0.98% in The Home Depot, Inc. (NYSE:HD). Fifth Third Bank owns 1.04M shares.

Alethea Capital Management Llc, which manages about $155.00M and $58.55M US Long portfolio, decreased its stake in Spdr Series Trust (XBI) by 10,344 shares to 3,517 shares, valued at $335,000 in 2018Q2, according to the filing.

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 24 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by FBR Capital with “Buy” on Friday, March 9. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Wednesday, January 17 by FBR Capital. The firm earned “Buy” rating on Friday, February 2 by FBR Capital. B. Riley & Co maintained the stock with “Buy” rating in Friday, December 1 report. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by H.C. Wainwright on Monday, December 11. The rating was reinitiated by H.C. Wainwright on Tuesday, November 14 with “Buy”. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by H.C. Wainwright on Wednesday, August 12. FBR Capital maintained TG Therapeutics, Inc. (NASDAQ:TGTX) on Monday, December 11 with “Buy” rating. The stock has “Buy” rating by SunTrust on Friday, May 27. The firm earned “Buy” rating on Thursday, June 15 by FBR Capital.

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Globenewswire.com which released: “CLASS ACTION UPDATE for TGTX, ALNY and TRVN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders – GlobeNewswire” on November 21, 2018, also Businesswire.com with their article: “Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of TG Therapeutics, Inc. Investors (TGTX) – Business Wire” published on November 16, 2018, Seekingalpha.com published: “TG Therapeutics: An Immunology Powerhouse – Seeking Alpha” on June 14, 2018. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: Nasdaq.com and their article: “Analysts Estimate TG Therapeutics (TGTX) to Report a Decline in Earnings: What to Look Out for – Nasdaq” published on November 07, 2018 as well as Seekingalpha.com‘s news article titled: “TG Therapeutics backs away from response rate endpoint in late-stage study of U2 in CLL, accelerated approval off the table; shares down 44% premarket – Seeking Alpha” with publication date: September 25, 2018.

Investors sentiment increased to 1.47 in Q2 2018. Its up 0.01, from 1.46 in 2018Q1. It is positive, as 17 investors sold TGTX shares while 28 reduced holdings. 22 funds opened positions while 44 raised stakes. 39.66 million shares or 5.82% more from 37.47 million shares in 2018Q1 were reported. Metropolitan Life Communications reported 0% stake. California Public Employees Retirement Systems holds 0% or 92,600 shares in its portfolio. Piedmont Inv Llc accumulated 1,027 shares or 0% of the stock. Tci Wealth Advsrs has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 100 shares. Mackay Shields Limited Liability Company holds 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX) for 28,200 shares. Jacobs Levy Equity Mngmt Inc reported 0.01% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Manufacturers Life Insurance Company The owns 42,963 shares. Hikari Power Ltd invested in 160,000 shares. Prelude Capital Management Limited Liability Corporation owns 78 shares. Fifth Third Bank & Trust invested in 0% or 6,600 shares. Teacher Retirement Sys Of Texas has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Deutsche Bancshares Ag holds 0% in TG Therapeutics, Inc. (NASDAQ:TGTX) or 94,171 shares. Hanseatic Management holds 114 shares. Jefferies Grp Inc Limited Company accumulated 4,800 shares or 0% of the stock. Voya Invest Mngmt Ltd Llc reported 0% stake.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.